Document text
Principal Investigator: Mary Szatkowski Ozers
Organization: PROTEOVISTA, LLC
Fiscal Year: 2020
Award: $129,050
Funding agency: National Cancer Institute
This application is being submitted as an Administrative Supplement in response to the Notice of Special Interest (NOSI) identified as NOT-CA-20-042. Study of highly infectious diseases, especially those caused by viruses, poses unique biosafety challenges to the scientific research community. Rather than lose the insights this research can provide, common workarounds exist to reduce the risk of studying infectious virus by examining the proteins encoded by the virus in the absence of a fully infectious particle. This approach has been employed for many other viruses and has been proven effective in obtaining valuable data. However, viruses like SARS-CoV-2 mutate leading to many different strains and sequence variations, and it can be difficult to predict which mutations alter virus transmission, infection symptoms, or vaccine / treatment efficacy. Given that cancer patients constitute an at-risk population for Covid-19, this is even more complicated in the context of how cancer cells affect virus infection or how the virus affects cancer progression. Methods to examine virus protein mutations in a high throughput, systematic, and comprehensive (i.e. every mutation) manner are completely lacking. To help address this challenge, we propose to harness our innovative high throughput mutagenesis strategy to comprehensively generate plasmids of every possible point mutation of the SARS-CoV-2 S “spike” protein as the key viral recognition protein of the human entry receptor, towards accelerating functional studies and vaccine development. The resulting plasmid set is especially useful for functional assays to identify critical S protein variants, which is a vital area of current Covid-19 research. The S protein mutant plasmid set will be validated by expression of the variant plasmids in human cells and determination of which variants bind to different commercially available SARS-CoV-2 S protein antibodies. These results will be confirmed by immunofluorescence staining. While we envision these variants being employed by the cancer research community in their model systems, they can be used equally effectively by the SARS-CoV-2 research community in general. The proposed method significantly improves on random mutagenesis by error-prone PCR by avoiding its substantial mutational bias and ensuring exactly one mutation per plasmid for streamlined analysis. This strategy will be confirmed by next generation sequencing (NGS), comparing against error-prone PCR. Following successful validation assays for the S protein variant pool, we will generate mutant plasmid sets for three additional key proteins encoded by the SARS-CoV-2 genome. This Administrative Supplement is within the scope of our parent IMAT award, which is a technology development R21 mechanism, to generate all mutants of three key oncoproteins and link the expressed protein variants back to specific feature locations on a microarray. Upon successful completion of this Administrative Supplement, we intend to prepare a SBIR Phase I to sort each individual SARS-CoV-2 mutant plasmid into distinct wells of multiwell plates for additional availability to the Covid-19 research community.
Terms: <2019 novel coronavirus><2019-nCoV><Address><Administrative Supplement><Affect><Amino Acid Substitution><Antibodies><Area><Assay><Award><Back><Binding><Bioassay><Biologic Assays><Biologic Models><Biological Assay><Biological Models><COVID-19><COVID19><Cancer Patient><Cell Body><Cells><Collection><Communicable Diseases><Communities><Data><Development><Dorsum><Drugs><Ensure><Exploratory/Developmental Grant><Genetic Alteration><Genetic Change><Genetic defect><Genetics-Mutagenesis><Genome><Human><Immunofluorescence><Immunofluorescence Immunologic><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Link><Location><Malignant Cell><Medication><Methods><Model System><Modern Man><Molecular Interaction><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><NGS Method><NGS system><Oncogene Products><Oncogene Proteins><Oncoproteins><Parents><Pathogenicity><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Plasmids><Point Mutation><Populations at Risk><Protein Array><Proteins><R21 Mechanism><R21 Program><Receptor Cell><Receptor Protein><Research><Risk><S-nitro-N-acetylpenicillamine><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><SBIR><SNAP><Severe acute respiratory syndrome coronavirus 2><Small Business Innovation Research><Small Business Innovation Research Grant><Staining method><Stains><Symptoms><Treatment Efficacy><Vaccines><Validation><Variant><Variation><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral Structural Proteins><Virus><Virus Diseases><Wuhan coronavirus><anti-cancer research><anticancer research><cancer cell><cancer progression><cancer research><cell determination><corona virus disease 2019><coronavirus disease 2019><density><develop a vaccine><development of a vaccine><developmental><drug/agent><exploratory developmental study><genome mutation><improved><innovate><innovation><innovative><insight><interest><intervention efficacy><mutant><mutation scanning><mutation screening><neoplasm progression><neoplastic progression><next gen sequencing><next generation sequencing><nextgen sequencing><novel><particle><receptor><response><tech development><technology development><therapeutic efficacy><therapeutically effective><therapy efficacy><tumor progression><vaccine development><vaccine formulation><viral infection><viral transmission><virus infection><virus protein><virus transmission><virus-induced disease>